Dicerna Pharmaceuticals, Inc.
DRNA
DRNA was delisted on the 27th of December, 2021.
55 hedge funds and large institutions have $79.7M invested in Dicerna Pharmaceuticals, Inc. in 2016 Q1 according to their latest regulatory filings, with 4 funds opening new positions, 19 increasing their positions, 17 reducing their positions, and 7 closing their positions.
12% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
5% less funds holding
Funds holding: 58 → 55 (-3)
43% less first-time investments, than exits
New positions opened: 4 | Existing positions closed: 7
57% less capital invested
Capital invested by funds: $185M → $79.7M (-$105M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$759K |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$404K |
| 3 |
State Street
Boston,
Massachusetts
|
+$226K |
| 4 |
Renaissance Technologies
New York
|
+$189K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$173K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.3M |
| 2 |
Millennium Management
New York
|
-$1.72M |
| 3 |
Morgan Stanley
New York
|
-$826K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$321K |
| 5 |
AQR Capital Management
Greenwich,
Connecticut
|
-$320K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
Bank of Montreal
Toronto,
Ontario, Canada
| $13K | +$13.8K | +2,186 | +1,145% |
|
52
Bank of America
Charlotte,
North Carolina
| $11K | -$11.8K | -1,870 | -49% |
|
|
TRCT
53
Tower Research Capital (TRC)
New York
| $7K | -$18.5K | -2,935 | -70% |
|
54
BlackRock
New York
| $1K | +$1.36K | +216 | New |
|
55
Geode Capital Management
Boston,
Massachusetts
| $544 | +$8.65K | +1,371 | +1% |
|
|
PP
56
PDT Partners
New York
| – | -$235K | -19,833 | Closed |
|
|
CS
57
Credit Suisse
Zurich,
Switzerland
| – | -$189K | -15,886 | Closed |
|
|
MLICM
58
Metropolitan Life Insurance Company (MetLife)
New York
| – | -$141K | -11,866 | Closed |
|
|
PAM
59
Panagora Asset Management
Boston,
Massachusetts
| – | -$81K | -6,819 | Closed |
|
60
BNP Paribas Financial Markets
Paris,
France
| – | -$37.5K | -3,156 | Closed |
|
61
UBS Group
Zurich,
Switzerland
| – | -$3K | -242 | Closed |
|
DRNA Hedge Fund Activity: Q1 2016 in Review
55 of the 3,753 institutional investors tracked by Wall St. Rank reported a position in Dicerna Pharmaceuticals, Inc. (DRNA) for Q1 2016, worth a combined $79.7M — down 57% from $185M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of DRNA and 4 opened new positions — a net loss of 3 holders — while 17 trimmed existing stakes and 19 added.
The largest buyer was Oxford Asset Management, adding an estimated $759K. The largest seller was Wellington Management Group, cutting an estimated $2.3M.
- 55 institutional investors held Dicerna Pharmaceuticals, Inc. (DRNA) as of Q1 2016, down from 58 in Q4 2015.
- Funds reported $79.7M of Dicerna Pharmaceuticals, Inc. stock for Q1 2016, down 57% quarter-over-quarter.
- 4 funds opened new Dicerna Pharmaceuticals, Inc. positions in Q1 2016 and 7 closed out, a net change of -3 holders.
- The largest Dicerna Pharmaceuticals, Inc. buyer in Q1 2016 was Oxford Asset Management, an estimated $759K added.
- The largest Dicerna Pharmaceuticals, Inc. seller in Q1 2016 was Wellington Management Group, an estimated $2.3M sold.
Based on aggregated 13F filings for Q1 2016.